Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Kinetics Of Chronic Lymphocytic Leukemia Cells In Tissues and Blood During Therapy With The BTK Inhibitor Ibrutinib

Dominik Wodarz, Naveen Garg, Natalia L. Komarova, Ohad Benjamini, MD, Michael J. Keating, MD, William G. Wierda, M.D., Ph.D, Hagop M. Kantarjian, MD, Danelle F. James, MD, Susan M. O'Brien, MD, Jan A. Burger, MD, PhD

Blood (2013) 122 (21): 4166.

https://doi.org/10.1182/blood.V122.21.4166.4166

Published: 2013

Journal Articles

Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL).

Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Deborah A. Thomas, MD, Stefan Faderl, MD, Dan Jones, MD, PhD, Charles A Koller, MD, Samuel Dara, Rebecca Garris, Partow Kebriaei, MD, Richard Champlin, MD, Gautam Borthakur, MD, William G. Wierda, M.D., Ph.D, Jan A. Burger, MD, PhD, Jorge Cortes, MD, Susan O'Brien

Blood (2009) 114 (22): 837.

https://doi.org/10.1182/blood.V114.22.837.837

Published: 2009

Journal Articles

Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes.

Xavier C. Badoux, MBBS, Michael Keating, MD, Susan O'Brien, MD, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Tapan Kadia, MD, Lynne V Abruzzo, MD, PhD, William G. Wierda, M.D., Ph.D

Blood (2009) 114 (22): 1248.

https://doi.org/10.1182/blood.V114.22.1248.1248

Published: 2009

Journal Articles

Characteristics and Outcome of Patients with Acute Myeloid Leukemia (AML) Refractory to One Cycle of High Dose Cytarabine-Based Induction Chemotherapy.

Farhad Ravandi, M.D., Jorge Cortes, MD, Stefan Faderl, MD, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD, PhD, Marcos de Lima, MD, Sherry Pierce, RN, Mark Brandt, Gautam Borthakur, MD, Alessandra Ferrajoli, MD., William G. Wierda, M.D., Ph.D, Charles A Koller, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 1038.

https://doi.org/10.1182/blood.V114.22.1038.1038

Published: 2009

Journal Articles

Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia.

Sameer A Parikh, MD, Michael Keating, MD, Susan O'Brien, Alessandra Ferrajoli, Stefan Faderl, MD, Charles Koller, MD, Zeev Estrov, Susan Lerner, M.S., RHIA, William G. Wierda, M.D., Ph.D

Blood (2009) 114 (22): 208.

https://doi.org/10.1182/blood.V114.22.208.208

Published: 2009

Journal Articles

Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).

Xavier C. Badoux, MBBS, Michael Keating, MD, Susan O'Brien, MD, Tapan Kadia, MD, Alessandra Ferrajoli, MD., Stefan Faderl, MD, Charles Koller, MD, Guillermo Garcia-Manero, MD, Jan A. Burger, MD, PhD, William G. Wierda, M.D., Ph.D,

Blood (2009) 114 (22): 3431.

https://doi.org/10.1182/blood.V114.22.3431.3431

Published: 2009

Journal Articles

Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL).

Nicolas Batty, MD, Xavier C. Badoux, MBBS, Michael Keating, MD, E. Lin, Susan Lerner, M.S., RHIA, Susan O'Brien, Alessandra Ferrajoli, MD., Tapan Kadia, MD, Jan A. Burger, MD, PhD, Stefan Faderl, MD, William G. Wierda, M.D., Ph.D

Blood (2009) 114 (22): 3448.

https://doi.org/10.1182/blood.V114.22.3448.3448

Published: 2009

Journal Articles

The Immunophenotype Signature CD49d + CD38 + Identifies Chronic Lymphocytic Leukemia Cases with a Higher Potential for Migration Beneath Marrow Stromal Cells.

Antonina Kurtova, M.S., Mariela Sivina, Ph.D., Maite P. Quiroga, B.S., William G. Wierda, M.D., Ph.D, Michael J. Keating, MD, Jan A. Burger, M.D., Ph.D.

Blood (2009) 114 (22): 356.

https://doi.org/10.1182/blood.V114.22.356.356

Published: 2009

Journal Articles

Long Term Outcome Following Treatment Failure of FCR Chemoimmunotherapy as Initial Therapy for Chronic Lymphocytic Leukemia.

Michael J. Keating, M.B., B.S., William G. Wierda, M.D., Ph.D, Constantine S. Tam, M.B., B.S., Alice Lynn, Susan O'Brien, M.D., Susan Lerner, M.S., RHIA, Hagop M. Kantarjian, M.D.

Blood (2009) 114 (22): 2381.

https://doi.org/10.1182/blood.V114.22.2381.2381

Published: 2009

Journal Articles

Current Leukemia Free Survival After Tyrosine Kinase Inhibitor (TKI) for Chronic Myeloid Leukemia (CML): A New Method That Accounts for Restoring Response with Sequential TKI.

Aref Al-Kali, MD, Hagop Kantarjian, MD, Jianqin Shan, William G. Wierda, M.D., Ph.D, Gautam Borthakur, MD, Zeev Estrov, MD, Srdan Verstovsek, MD, PhD, Susan O'Brien, M.D., Jorge Cortes, MD

Blood (2009) 114 (22): 2197.

https://doi.org/10.1182/blood.V114.22.2197.2197

Published: 2009

Journal Articles

Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): The MD Anderson Cancer Center (MDACC) Experience

Naveen Pemmaraju, Hagop M. Kantarjian, Farhad Ravandi, MBBS, Susan O’Brien, William G. Wierda, M.D., Ph.D, Deborah A. Thomas, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Sherry Pierce, Jorge Cortes, MD

Blood (2008) 112 (11): 3982.

https://doi.org/10.1182/blood.V112.11.3982.3982

Published: 2008

Journal Articles

Pim Kinase Inhibitor, SGI-1776, Induces Apoptosis in CLL Lymphocytes

Lisa S Chen, Ph.D, William G Wierda, M.D., Ph.D, Sanjeev Redkar, Ph.D, David J. Bearss, PhD, Varsha Gandhi, Ph.D

Blood (2008) 112 (11): 4199.

https://doi.org/10.1182/blood.V112.11.4199.4199

Published: 2008

Journal Articles

An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Andrew W. Roberts, MBBS, PhD, Jennifer Brown, MD, PhD, John F. Seymour, M.D., William G. Wierda, M.D., Ph.D, Thomas J. Kipps, MD, PhD, Hao Xiong, Ph.D., Yi-Lin Chiu, PhD, Todd Busman, PhD, Raymond A. Knight, MBA, Sari Enschede, MD, Andrew Krivoshik, MD, PhD, Rod Humerickhouse, MD, PhD

Blood (2008) 112 (11): 3177.

https://doi.org/10.1182/blood.V112.11.3177.3177

Published: 2008

Journal Articles

Standardizing Co-Culture Conditions Between Chronic Lymphocytic Leukemia Cells and Marrow Stromal Cells: Towards a Reliable and Reproducible System to Assess Cell Adhesion-Mediated Drug Resistance

Antonina Kurtova, MS, Maite P. Quiroga, BS, William G. Wierda, M.D., Ph.D, Michael Keating, MB, BS, Jan A. Burger, MD, PhD

Blood (2008) 112 (11): 3149.

https://doi.org/10.1182/blood.V112.11.3149.3149

Published: 2008

Journal Articles

Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.

Weigang Tong, M.D., Ph.D., Hagop Kantarjian, M.D., Susan O’Brien, M.D., Stefan Faderl, MD, Farhad Ravandi, MBBS, William G Wierda, M.D., Ph.D., Steven Kornblau, M.D., Gautam Borthakur, M.D., Guillermo Garcia-Manero, M.D., Elizabeth Burton, Mary Beth Rios, Jorge Cortes, M.D.

Blood (2008) 112 (11): 2126.

https://doi.org/10.1182/blood.V112.11.2126.2126

Published: 2008

Journal Articles

Life after Fludarabine, Cyclophosphamide, & Rituximab (FCR) - the Clinical Outcome of Patients with Chronic Lymphocytic Leukemia Who Receive Salvage Treatment after Frontline FCR.

Constantine S. Tam, William G. Wierda, M.D., Ph.D, Susan O’Brien, Susan Lerner, Issa F Khouri, Hagop M. Kantarjian, Michael J Keating, M.D.

Blood (2008) 112 (11): 2090.

https://doi.org/10.1182/blood.V112.11.2090.2090

Published: 2008

Journal Articles

Predicting Time to Initial Treatment in Early Stage CLL - Integration of Classical and Novel Prognostic Factors.

Michael J. Keating, M.B., B.S., Susan Lerner, Xuemei Wang, Laura Z. Rassenti, Ph.D., Susan O’Brien, M.D., Thomas J. Kipps, M.D., Ph.D., William G. Wierda, M.D., Ph.D

Blood (2008) 112 (11): 2093.

https://doi.org/10.1182/blood.V112.11.2093.2093

Published: 2008

Journal Articles

Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Deborah A. Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, William G. Wierda, M.D., Ph.D, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Jorge Cortes, MD, Charles A. Koller, MD, Gautam Borthakur, MBBS, Zeev Estrov, Marina Konopleva, MD, PhD, Farhad Ravandi, MBBS, Guillermo Garcia- Manero, MD, Susan O’Brien, M.D.

Blood (2008) 112 (11): 1931.

https://doi.org/10.1182/blood.V112.11.1931.1931

Published: 2008

Journal Articles

Treatment with Lenalidomide Has a Positive Immunomodulatory Effect in Patients with Chronic Lymphocytic Leukemia.

Hui Gao, PhD, Alessandra Ferrajoli, MD, Evan N Cohen, Bang-Ning Lee, PhD, Sanda Tin, M.D., Susan O’Brien, M.D., William G. Wierda, M.D., Ph.D, Zeev Estrov, M.D., Stefan Faderl, MD, Michael J Keating, M.D., James M. Reuben, PhD

Blood (2008) 112 (11): 2107.

https://doi.org/10.1182/blood.V112.11.2107.2107

Published: 2008

Journal Articles

Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression.

Emanuela M. Ghia, PhD, Laura Z. Rassenti, Ph.D., George F. Widhopf, Ph.D., Donna S. Neuberg, Ph.D., Michael J. Keating, M.D., William G. Wierda, M.D., Ph.D., John G. Gribben, M.D., Jennifer R. Brown, M.D., Ph.D., Ian W. Flinn, M.D., Ph.D., Kanti R. Rai, M.D., John C. Byrd, M.D., Neil E. Kay, M.D., Andrew W. Greaves, B.S., Thomas J. Kipps, M.D.,Ph.D.

Blood (2006) 108 (11): 2774.

https://doi.org/10.1182/blood.V108.11.2774.2774

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Kinetics Of Chronic Lymphocytic Leukemia Cells In Tissues and Blood During Therapy With The BTK Inhibitor Ibrutinib

Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL).

Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes.

Characteristics and Outcome of Patients with Acute Myeloid Leukemia (AML) Refractory to One Cycle of High Dose Cytarabine-Based Induction Chemotherapy.

Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia.

Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).

Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL).

The Immunophenotype Signature CD49d + CD38 + Identifies Chronic Lymphocytic Leukemia Cases with a Higher Potential for Migration Beneath Marrow Stromal Cells.

Long Term Outcome Following Treatment Failure of FCR Chemoimmunotherapy as Initial Therapy for Chronic Lymphocytic Leukemia.

Current Leukemia Free Survival After Tyrosine Kinase Inhibitor (TKI) for Chronic Myeloid Leukemia (CML): A New Method That Accounts for Restoring Response with Sequential TKI.

Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): The MD Anderson Cancer Center (MDACC) Experience

Pim Kinase Inhibitor, SGI-1776, Induces Apoptosis in CLL Lymphocytes

An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Standardizing Co-Culture Conditions Between Chronic Lymphocytic Leukemia Cells and Marrow Stromal Cells: Towards a Reliable and Reproducible System to Assess Cell Adhesion-Mediated Drug Resistance

Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.

Life after Fludarabine, Cyclophosphamide, & Rituximab (FCR) - the Clinical Outcome of Patients with Chronic Lymphocytic Leukemia Who Receive Salvage Treatment after Frontline FCR.

Predicting Time to Initial Treatment in Early Stage CLL - Integration of Classical and Novel Prognostic Factors.

Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Treatment with Lenalidomide Has a Positive Immunomodulatory Effect in Patients with Chronic Lymphocytic Leukemia.

Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only